📬 Lung/Head and Neck/Thymoma Intelligence Digest — Week 2026-W27
Sigvotatug vedotin's phase 3 SigVie-002 missed OS in pretreated nonsquamous NSCLC, while JCOG1008 5-year data confirmed weekly cisplatin, ctDNA MRD predicted relapse after durvalumab, and aumolertinib offered a toxicity-driven switch for osimertinib-intolerant patients.
⚡ TL;DR
📄 Publications
- Targeting drug-tolerant persister cells: Let's bring on the TROPs! — TROP2 identified as an EGFR-TKI-induced vulnerability in drug-tolerant persister lung cancer cells
- Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer. — c-Myc represses TROP2 and TKI-mediated MAPK inhibition reduces c-Myc, leading to TROP2 upregulation
- A Phase 2 Feasibility Study Combining Pembrolizumab and Metformin in patients with Metastatic Head and Neck Cancer. — ORR of 50% with metformin plus pembrolizumab in R/M HNSCC
- Brief Report: Proposed clinical trial guidelines based on clinicopathological heterogeneity of metastatic pulmonary large cell neuroendocrine carcinoma (LCNEC). — Median OS 10.0 months for primary LCNEC and 16.3 months for tLCNEC
- Amivantamab induces immune-mediated cytotoxicity in mesothelioma via EGFR and MET engagement. — Amivantamab induced dose-dependent cytotoxicity via NK cell-mediated ADCC in mesothelioma
🐦 Twitter / 🦋 Bluesky
- Time-of-day immunotherapy NSCLC trial retracted — The phase III time-of-day immunochemotherapy NSCLC trial in Nature Medicine has been officially retracted
- CheckMate 227 early detriment analysis: rapid progression risk with first-line nivo/ipi — Rapid progression occurred in 40% with 1L nivo/ipi vs 26% with chemo, associated with high NLR, low TMB, PDL1 0%, low albumin, high M-MDSC
- ctDNA-based MRD predicts relapse during and after durvalumab in stage III NSCLC — Detectable ctDNA at cycle 7 and post-treatment was associated with inferior PFS (HR 2.45 and 5.37)
- JCOG1008 5-year update confirms weekly cisplatin in postoperative head and neck cancer — 5-year OS 71.2% with weekly cisplatin vs 58.7% with 3-weekly, HR 0.76, noninferiority confirmed
- Sex-based differences in tolerability of developmental ADCs in NSCLC — Women had higher grade ≥2 TRAEs (82.8 vs 69.1%, OR 2.8) and more dose reductions (OR 3.35) in early-phase ADC trials
Full details below ↓
📄 What's Being Published
Targeting drug-tolerant persister cells: Let's bring on the TROPs! — Izumi Motohiro et al., Cancer Cell
Liao et al. identify TROP2 as an EGFR tyrosine kinase inhibitor-induced vulnerability in drug-tolerant persister lung cancer cells. Anti-TROP2 antibody-drug conjugates target this residual population, supporting an "induce-target-kill" strategy to delay resistance and extend the benefit of EGFR tyrosine kinase inhibition.
Clinical bottom line: This commentary frames anti-TROP2 ADCs as a strategy to delay EGFR-TKI resistance by targeting drug-tolerant persister cells.
Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer. — Liao Jun et al., Cancer Cell
Mechanistically, c-Myc acts as a transcriptional repressor of TROP2, and TKI-mediated MAPK pathway inhibition reduces c-Myc levels, leading to TROP2 upregulation. Combining the TROP2-targeting ADC sacituzumab tirumotecan (sac-TMT) with osimertinib effectively suppresses DTP emergence and delays tumor relapse in preclinical models.
Clinical bottom line: New mechanistic data show c-Myc repression of TROP2 underlies persister-cell upregulation, and an ongoing phase 2 trial of first-line sac-TMT plus osimertinib shows preliminary efficacy.
A Phase 2 Feasibility Study Combining Pembrolizumab and Metformin in patients with Metastatic Head and Neck Cancer. — Zamulko Olga et al., Clin Cancer Res
Eighteen patients were evaluable for response, including 4 complete and 5 partial responses for an ORR of 50% (95% CI [29, 71]). Five Grade 3 AEs occurred, including nausea, diarrhea, fatigue, and weight loss.
Clinical bottom line: Metformin added to pembrolizumab was well tolerated and produced encouraging response rates in R/M HNSCC, supporting a randomized trial.
Brief Report: Proposed clinical trial guidelines based on clinicopathological heterogeneity of metastatic pulmonary large cell neuroendocrine carcinoma (LCNEC). — Choudhury Noura J et al., J Thorac Oncol
Median overall survival from start of first-line therapy was 10.0 months (95% CI 8.6–11.9) for patients with primary LCNEC and 16.3 months (9.4–40) for tLCNEC. There was no statistical difference in OS between patients treated with NSCLC- or SCLC-regimens (mOS 12.1 [10.0–17.6] vs 9.4 months [6.3–11.2]).
Clinical bottom line: Outcomes in metastatic LCNEC are poor and not clearly improved by molecularly-classified standard regimens, motivating prospective trials of novel therapeutics.
Amivantamab induces immune-mediated cytotoxicity in mesothelioma via EGFR and MET engagement. — Suzuki Shinichiro et al., J Thorac Oncol
Co-culture experiments demonstrated that amivantamab induced dose-dependent cytotoxicity via NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC). In multiple mesothelioma PDX models, the combination of amivantamab and NK cells significantly reduced tumor growth without overt toxicity.
Clinical bottom line: Preclinical data support clinical evaluation of bispecific EGFR/MET-targeting antibodies in mesothelioma through innate immune-mediated cytotoxicity.
VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC. — Roulleaux-Dugage Matthieu et al., J Immunother Cancer
In IMpower150, the addition of bevacizumab to CT+IT significantly improved progression-free survival (HR: 0.49) and OS (HR: 0.52) in liver-metastasis-positive patients — an effect not observed in patients without liver metastases. In IMpower130, liver-metastasis-positive patients derived no overall survival benefit from CT plus IT compared with CT alone (HR for OS: 1.05; 95% CI 0.63 to 1.73).
Clinical bottom line: Adding bevacizumab to chemoimmunotherapy was associated with improved survival specifically in non-squamous NSCLC patients with liver metastases.
Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in patients with metastatic NSCLC: the phase II RECLAIM trial. — Ulas Ezgi B et al., J Immunother Cancer
ORR was 7% and 10% at 6 and 12 weeks, and reached 29% as the best response in PD-L1 low/negative NSCLC patients treated with IPI/NIVO/RT after anti-PD-1 progression. Median OS by best response was 3.1, 13.5, and 22.5 months for progressive disease, stable disease, and partial/complete response (p<0.001).
Clinical bottom line: IPI/NIVO with subablative radiotherapy induced objective responses in a subset of PD-L1 low/negative NSCLC patients progressing after first-line anti-PD-1 therapy.
Brief Report: Aumolertinib as a Switch Therapy in Osimertinib-Intolerant NSCLC: The ACTIVE Trial. — Li Ziming et al., J Thorac Oncol
The 3-month conversion success rate was 70.6% (95% CI: 52.5, 84.9) in the evaluable population, with 78.9% in the non-hematologic toxicity subgroup and 60.0% in the hematologic toxicity subgroup. Median post-switch progression-free survival was 11.6 months, and the 3-year post-switch overall survival rate was 52.4%.
Clinical bottom line: Toxicity-driven switching to aumolertinib achieves sustained efficacy and manageable safety in osimertinib-intolerant EGFR-mutant advanced NSCLC.
ctDNA based MRD detection in stage III NSCLC treated with chemoradiotherapy and durvalumab. — Horndalsveen Henrik et al., J Thorac Oncol
Detectable ctDNA before the seventh cycle of durvalumab and three months after treatment completion was strongly associated with inferior progression-free survival (HR: 2.45; 95% CI: 1.18–5.11; p = 0.013 and HR: 5.37; 95% CI: 1.93–14.93; p < 0.001, respectively). ctDNA detection after CRT but before durvalumab initiation was not prognostic (HR: 1.38; 95% CI: 0.78–2.41; p = 0.269).
Clinical bottom line: Serial ctDNA-based MRD assessment during and after durvalumab identifies stage III NSCLC patients at high risk of relapse who could benefit from intensified strategies.
Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma. — Vujanovic Lazar et al., Clin Cancer Res
Patients with PD-L1 CPS≥20 showed numerically lower DFS than those with CPS<20; however, higher densities of PD-L1+ stromal cells were associated with more favorable outcomes. Elevated serum arginase-1 was associated with inferior DFS, while higher levels of GM-CSF, IL-2, and nectin-2 were associated with more favorable outcomes.
Clinical bottom line: Multiple tumoral and systemic immune correlates of adjuvant pembrolizumab with CRT in high-risk HNSCC merit validation in larger trials.
Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer. — Tahara Makoto et al., J Clin Oncol
5-year OS was 58.7% in the 3-weekly arm and 71.2% in the weekly arm (hazard ratio, 0.76 [95% CI, 0.52 to 1.12]), confirming the noninferiority of the weekly regimen. No late adverse event showed more than a 10% difference between the two arms.
Clinical bottom line: At 5.6 years median follow-up, weekly cisplatin plus radiotherapy is confirmed noninferior in OS to 3-weekly cisplatin for postoperative high-risk LA-SCCHN.
Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer. — Borghaei Hossein et al., Clin Cancer Res
Rapid progression rates were 40% with nivolumab plus ipilimumab versus 26% with chemotherapy. Early detriment was not observed with nivolumab plus ipilimumab with chemotherapy across subgroups from CheckMate 9LA.
Clinical bottom line: Specific biomarkers identify metastatic NSCLC patients at risk of early detriment from first-line nivolumab plus ipilimumab, a risk mitigated by adding chemotherapy.
Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer. — Matsumoto Kinnosuke et al., Eur J Cancer
Preexisting ILD was independently associated with higher risks of any-grade pneumonitis (adjusted sHR, 2.64; 95% CI, 1.91–3.65) and grade ≥3 pneumonitis (adjusted sHR, 2.18; 95% CI, 1.37–3.47), and with worse OS (adjusted HR, 1.36; 95% CI, 1.12–1.66). Probable UIP/UIP pattern was associated with higher pneumonitis risk (adjusted sHR, 2.18; 95% CI, 1.27–3.74) and shorter OS (adjusted HR, 2.88; 95% CI, 1.80–4.61).
Clinical bottom line: Pretreatment HRCT evaluation of preexisting ILD, especially UIP pattern, aids individualized risk-benefit assessment before first-line ICI therapy in NSCLC.
Turnaround Time of Comprehensive Genomic Profiling in Lung Cancer and Other Solid Tumors. — Fox Adam H et al., JCO Oncol Pract
The overall turnaround time from specimen collection to CGP results reporting decreased from a median of 43 days (IQR, 31–72) to 32 days (IQR, 22–51) from 2018 to 2024. Delay in the time from biopsy to CGP ordering was the largest contributor to protracted TAT and varied between clinical sites.
Clinical bottom line: Genomic profiling turnaround has improved but ordering delays remain the biggest bottleneck and likely contribute to suboptimal patient care.
STS Expert Consensus Document (2026) on Addressing Definition and Practices of Sublobar Resection in Non-small Cell Lung Cancer. — Khullar Onkar V et al., Ann Thorac Surg
Three rounds of voting were required to reach >75% agreement on 21 statements to help guide appropriate utilization of sublobar resection in early-stage lung cancer. Two recent randomized clinical trials have shown sublobar resection to be non-inferior to lobectomy in node-negative NSCLC ≤2 cm.
Clinical bottom line: New STS consensus statements provide guidance on appropriate use of sublobar resection in early-stage NSCLC.
Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors. — Derbala Mohamed H et al., J Immunother Cancer
A baseline iTIL of ≥60 cells/mm² was associated with favorable PFS (HR 0.49, 95% CI 0.25 to 0.99, p=0.046) and higher CD8+ and CD8+PD-1+ and lower FoxP3+CD8+PD-1+ T-cell density. The combination of increased iTIL and decreased tumor content was significantly associated with better PFS (HR 0.36, p=0.009) and OS (HR 0.36, p=0.029).
Clinical bottom line: AI-powered assessment of the tumor microenvironment before and during treatment may inform pembrolizumab outcomes in rare tumors.
Excessive vascular integrity restricts anti-tumor immunity. — Trotta Rosa et al., Cell
Wang et al. identify an immune-excluding vasculature in small-cell lung cancer, where excessive vessel integrity drives immune desertification, and propose "reverse normalization" to restore immune access and overcome immunotherapy resistance.
Clinical bottom line: A reverse-normalization strategy targeting excessive vessel integrity may restore immune access and overcome immunotherapy resistance in SCLC.
Limited predictive value of PD-L1 TPS for pathological response in NSCLC is not attributable to interobserver variability. — Steinestel Konrad et al., Lung Cancer
TPS remained poorly correlated with residual viable tumor for both single-rater assessment (r = −0.17, p = 0.38) and averaged TPS (r = −0.16, p = 0.39), with no significant difference between these approaches (p = 0.96). Interobserver agreement became near-perfect when mean scores per case were calculated across observers (ICC = 0.99).
Clinical bottom line: The poor predictive value of PD-L1 TPS for pathological response in neoadjuvant NSCLC reflects an intrinsic limitation of the biomarker, not interobserver variability.
Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD. — Okamoto Isamu et al., Lung Cancer
Confirmed ORR was 43% (80% confidence interval: 24–63), representing six partial responses. Median PFS was 4.2 months (95% CI: 3.0–5.6) and median overall survival was 10.2 months (95% CI: 4.3–16.8).
Clinical bottom line: Final ORCHARD data show durvalumab plus etoposide-platinum gives only a modest response in neuroendocrine-transformed EGFR-mutant NSCLC, with no clear standard established.
🗣️ What People Were Discussing This Week
How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).
Time-of-day immunotherapy NSCLC trial retracted
The phase III trial evaluating time-of-day immunochemotherapy in NSCLC, published in Nature Medicine, has been officially retracted due to major concerns regarding trial registration, protocol inconsistencies, and data integrity. Oncologists noted the retraction arrived after the paper had already accumulated citations, prompting direct questions about whether peer review adequately scrutinizes trial registration and data provenance in high-profile submissions.
Discussed by: @DraMartinezLago, @Alfdoc2, @PTarantinoMD
CheckMate 227 early detriment analysis: rapid progression risk with first-line nivo/ipi
An analysis of CheckMate 227 reported rapid progression in 40% of metastatic NSCLC patients receiving first-line nivolumab plus ipilimumab, compared with 26% with chemotherapy, with risk linked to high neutrophil-to-leukocyte ratio, low TMB, PD-L1 0%, low albumin, and higher-than-median baseline monocytic myeloid-derived suppressor cells. Critically, increased early detriment was not seen with nivolumab plus ipilimumab plus chemotherapy in CheckMate 9LA, raising the clinical question of whether biomarkers such as NLR, TMB, and M-MDSC should steer high-risk patients away from chemo-free dual immunotherapy.
Discussed by: @StephenVLiu, @MedwatchKate
ctDNA-based MRD predicts relapse during and after durvalumab in stage III NSCLC
Serial ctDNA monitoring in stage III NSCLC patients treated with chemoradiotherapy and durvalumab showed that detectable ctDNA at cycle 7 and post-treatment was associated with inferior PFS (HR 2.45 and HR 5.37, respectively). ctDNA was detected in 35% of patients after CRT but was not prognostic at that timepoint; however, patients who were ctDNA-positive at 6 months had a median PFS of 14.7 months versus 46.9 months in those who were ctDNA-negative (HR 2.45), framing the debate around whether serial MRD can reliably select patients for treatment intensification.
Discussed by: @HHorinouchi, @StephenVLiu, @RobertoBoreaMD
JCOG1008 5-year update confirms weekly cisplatin in postoperative head and neck cancer
Five-year OS was 71.2% with weekly cisplatin versus 58.7% with 3-weekly cisplatin (HR 0.76; 95% CI 0.52–1.12), confirming noninferiority of the weekly regimen. Five-year RFS was 64.3% versus 53.0% (HR 0.81), and the data prompted clinicians to debate whether this mature randomized evidence is sufficient to establish weekly cisplatin as the default standard postoperative CRT regimen for high-risk LA-SCCHN.
Discussed by: @DrRishabhOnco, @OncoAlert
Sex-based differences in tolerability of developmental ADCs in NSCLC
A study of early-phase ADC trials in lung cancer found that women had higher rates of grade ≥2 treatment-related adverse events (82.8% vs 69.1%; OR 2.8) and more dose reductions (OR 3.35) compared with men, while survival outcomes were the same. Clinicians discussed whether these sex-based tolerability differences should be incorporated into ADC dosing strategies and the design of future trials.
Discussed by: @HHorinouchi, @LungCancerEu
Pan-tumor analysis of pCR and ctDNA clearance after neoadjuvant/perioperative immunotherapy
A pan-tumor reconstructed individual patient data analysis encompassing 1,867 patients achieving pCR and 352 with ctDNA clearance across 8 tumor types found that 3-year event-free survival after pCR ranges from 78.6% in NSCLC to 100% in dMMR colorectal cancer, with no EFS benefit from postoperative adjuvant IO in patients who achieved pCR across trials. Specialists discussed whether this absence of adjuvant IO benefit after pCR supports de-escalating postoperative treatment in responders.
Discussed by: @ChristianRolfo, @YGaritaonaindia
SigVie-002: sigvotatug vedotin misses OS versus docetaxel in pretreated nonsquamous NSCLC
Sigvotatug vedotin, an IB6-directed ADC, failed to improve OS versus docetaxel in the phase 3 SigVie-002 trial in previously treated metastatic non-squamous NSCLC, though a signal was observed in the second-line setting. With an ongoing phase 3 study of sigvotatug vedotin plus pembrolizumab in first-line metastatic NSCLC with PD-L1 ≥50% still active, clinicians debated whether ADC development in NSCLC should pivot to biomarker-selected populations following this setback for the first-in-class IB6 target.
Discussed by: @ADesaiMD, @LuisRaezMD, @DrChoueiri, @TargetedOnc
Update: AENEAS2 conversation turns to pemetrexed cycle duration and combination value
Aumolertinib plus platinum/pemetrexed improved PFS versus aumolertinib alone in EGFR-mutant advanced NSCLC (28.9 vs 18.9 months; HR 0.47), but discussion focused on a cross-trial difference in pemetrexed duration: 13 cycles in FLAURA2 versus 20 cycles in AENEAS2. Oncologists debated whether the longer pemetrexed exposure in AENEAS2 complicates direct comparison of these combination first-line EGFR regimens.
Discussed by: @KatsuakiMaehara, @Oncologynewspro, @ASCOPost
🔥 Top Ranked Tweets
OncoAlert @OncoAlert
RT @JAMA_current: Among patients with EGFR-variant nonsquamous #NSCLC whose disease progressed after prior EGFR tyrosine kinase inhibitor therapy, the addition of ivonescimab to #chemotherapy improved overall survival compared with chemotherapy alone.
https://t.co/DrHsuvX2j5 https://t.co/Pcsd5Suvyd
🔖 3 ❤️ 27 🔁 9 👁 8,586
CancerNetwork® @CancerNetwrk
Sigvotatug vedotin, an investigational IB6-directed antibody drug conjugate, did not improve OS vs docetaxel in pretreated locally advanced nonsquamous NSCLC in the phase 3 SigVie-002 trial.
https://t.co/A441GtNmId
#lcsm #NSCLC #oncology https://t.co/gjTzEoCAne
🔖 0 ❤️ 1 🔁 0 👁 192
CancerNetwork® @CancerNetwrk
45-mg binimetinib tablets received tentative approval from the FDA for its ANDA to be used with encorafenib in BRAF V600E or V600K+ unresectable or metastatic melanoma, or for NSCLC with a BRAF V600E mutations.
https://t.co/v5U0CEBfXQ
#melsm #lcsm #NSCLC #oncology https://t.co/6X7O4Pbbf3
🔖 1 ❤️ 0 🔁 0 👁 187
Aakash Desai, MD, MPH, FASCO @ADesaiMD
RT @lungoncdoc: Ph 3 SigVie-002 Press Release
▫️Sigvotatug vedotin (IB-6 directed ADC) failed to improve OS vs docetaxel in previously treated metastatic non-squamous NSCLC. ▫️? Signal observed in 2L setting.
Negative study. Ongoing Ph 3 study of SV + pembro in 1L mNSCLC w/ PD-L1 ≥50% https://t.co/V9V3LPDbDx
🔖 2 ❤️ 24 🔁 10 👁 3,153
JAMA @JAMA_current
Among patients with EGFR-variant nonsquamous #NSCLC whose disease progressed after prior EGFR tyrosine kinase inhibitor therapy, the addition of ivonescimab to #chemotherapy improved overall survival compared with chemotherapy alone.
https://t.co/DrHsuvX2j5 https://t.co/Pcsd5Suvyd
🔖 3 ❤️ 27 🔁 9 👁 8,586
OncLive.com @OncLive
💥@US_FDA has granted priority review of neladalkib for TKI-pretreated ALK-positive NSCLC is supported by data from the phase 1/2 ALKOVE-1 trial.
Full details 📈: https://t.co/1TidgsfAcd
#oncology #lcsm
🔖 0 ❤️ 2 🔁 1 👁 501
Dr. Luis E. Raez @LuisRaezMD
Not good results for our patients and for the ones we have been working to get this drug approve it, there are patients that have benefit but probably overall we should have selected patients based on a biomarker to improve efficacy #lungcancer #lcsm
[Quoting @lungoncdoc: Ph 3 SigVie-002 Press Release
▫️Sigvotatug vedotin (IB-6 directed ADC) failed to improve OS vs docetaxel in previously treated metastatic non-squamous NSCLC. ▫️? Signal observed in 2L setting.
Negative study. Ongoing Ph 3 study of SV + pembro in 1L mNSCLC w/ PD-L1 ≥50% https://t.co/V9V3LPDbDx]
🔖 1 ❤️ 8 🔁 2 👁 2,621
Katsuaki Maehara 🇯🇵 @KatsuakiMaehara
⚠️ Pemetrexed Administration Cycles
🫁 In the FLAURA2 trial, pemetrexed was administered for 13 cycles, while in the AENEAS2 trial, it was administered for 20 cycles.
@ASCOPost
#LCSM
#nsclc
#egfr
#FLAURA2
#AENES2
[Quoting @ASCOPost: 🫁 Adding chemotherapy to aumolertinib may improve outcomes in EGFR+ advanced #NSCLC.
Phase III AENEAS2 trial data ➡️ combination therapy extended median PFS to 28.9 months vs 18.9 months with aumolertinib alone.
🔸 Shun Lu, MD, PhD | @TheLancetOncol
🔗 https://t.co/BmOZzqAs9c https://t.co/KEMXsjuUM5]
🔖 1 ❤️ 7 🔁 1 👁 1,435
Oncology News @Oncologynewspro
AENEAS2, a Chinese phase III trial published in @TheLancetOncol , showed aumolertinib + platinum/pemetrexed improved PFS vs aumolertinib alone in EGFR-mutant advanced NSCLC (28.9 vs 18.9 mo; HR 0.47). #NSCLC #EGFR #LungCancer #Oncology https://t.co/x27qKoUVr6
🔖 1 ❤️ 0 🔁 1 👁 61
The ASCO Post @ASCOPost
🫁 Adding chemotherapy to aumolertinib may improve outcomes in EGFR+ advanced #NSCLC.
Phase III AENEAS2 trial data ➡️ combination therapy extended median PFS to 28.9 months vs 18.9 months with aumolertinib alone.
🔸 Shun Lu, MD, PhD | @TheLancetOncol
🔗 https://t.co/BmOZzqAs9c https://t.co/KEMXsjuUM5
🔖 0 ❤️ 5 🔁 2 👁 2,001
JAMA @jama.com
Among patients with EGFR-variant nonsquamous #NSCLC whose disease progressed after prior EGFR tyrosine kinase inhibitor therapy, the addition of ivonescimab to #chemotherapy improved overall survival compared with chemotherapy alone.
ja.ma/4oGT6zG
🔖 0 ❤️ 0 🔁 0 👁 0
Oncology News @Oncologynewspro
Ivonescimab + chemotherapy improved OS in EGFR-mutant non-squamous NSCLC after EGFR-TKI progression in the phase 3 Chinese HARMONi-A trial. Median OS was 16.8 vs 14.1 months (HR 0.74; P=0.02). Supports immunotherapy benefit in this population. @JAMA_current #NSCLC #EGFR #Oncology https://t.co/HjqYOY6am6
🔖 0 ❤️ 0 🔁 0 👁 91
OncoAlert @OncoAlert
RT @DrRishabhOnco: 💥 JCOG1008 5-year update is here.
The long-standing debate over weekly vs 3-weekly cisplatin in postoperative head & neck cancer may finally have an answer.
📌 JCOG1008
👥 Postoperative high-risk LA-SCCHN
⚖️ Weekly cisplatin (40 mg/m²) + RT vs 3-weekly cisplatin (100 mg/m²) + RT
Key results (median follow-up: 5.6 years):
✅ 5-year OS
• 71.2% vs 58.7%
• HR 0.76 (95% CI 0.52-1.12)
• Noninferiority confirmed
✅ 5-year RFS
• 64.3% vs 53.0%
• HR 0.81
✅ 5-year Local RFS
• 68.8% vs 57.2%
• HR 0.79
🛡️ No clinically meaningful increase in late toxicity.
⬇️ Acute toxicity remained more favorable with weekly cisplatin.
🎯 Take-home:
Weekly cisplatin is no longer just the “more convenient” option.
It now has mature 5-year randomized data supporting it as a standard postoperative CRT regimen for high-risk LA-SCCHN.
Will this change your practice?
@ASCO @myESMO @oncoalert
#HeadNeckCancer #RadOnc #MedOnc
🔖 25 ❤️ 67 🔁 26 👁 4,649
OncoAlert @OncoAlert
RT @DrRishabhOnco: Most oncologists can name KEYNOTE, CheckMate, or EMPOWER.
But one PD-1 program has quietly stacked positive phase III trials across lung, esophageal, and gastric cancers.
The ASTRUM program 👇
🫁 ASTRUM-005 | ES-SCLC
Serplulimab + EP vs Placebo + EP
OS: 15.4 vs 10.9 mo
HR 0.63
🫁 ASTRUM-004 | Squamous NSCLC
Serplulimab + nab-paclitaxel/carboplatin vs chemo
PFS HR 0.53
OS HR 0.73
🍽️ ASTRUM-007 | ESCC
Serplulimab + FP vs Placebo + FP
OS: 15.3 vs 11.8 mo
HR 0.68
🍽️ ASTRUM-006 | Resectable PD-L1+ Gastric/GEJ
Peri-op Serplulimab + SOX → Adjuvant Serplulimab
vs
Peri-op SOX → Adjuvant SOX
EFS: HR 0.73
pCR: 21.6% vs 6.4%
4 cancers.
4 phase III wins.
While the oncology world focused on Western PD-1s, serplulimab quietly built one of the most successful immunotherapy development programs in cancer medicine.
Is ASTRUM the most underrated trial program in oncology?
@oncoalert @ASCO @myESMO
#Oncology #Immunotherapy #LungCancer #GastricCancer
🔖 23 ❤️ 69 🔁 26 👁 5,000
Stephen V Liu, MD @StephenVLiu
Value of immunotherapy is the long tail to the OS curve, but what about the other side of the KM? Report of CheckMate 227 (NSCLC) @CCR_AACR noted rapid progression with 1L nivo/ipi in 40% (vs 26% with chemo). Associated with high neutrophil:leukocyte ratio, low TMB, PDL1 0%, low albumin, higher-than-median baseline monocytic myeloid-derived suppressor cell (M-MDSC). Increased early detriment not seen with nivo/ipi plus chemo (CheckMate 9LA).
https://t.co/VAb19CwY5n
🔖 34 ❤️ 64 🔁 24 👁 5,450
Prepared by Rafael Santana-Davila, M.D. Questions or feedback? Just reply to this email.
Disclaimer: This digest is AI-generated. Content may contain errors -- always verify with original sources.
Know a colleague who would find this useful? Forward this email or have them subscribe here.
If you find this useful, ☕ buy me a coffee.